Published on October 28, 2009 at 7:55 AM
DUSA Pharmaceuticals, Inc.® (Nasdaq GM: DUSA), a specialty pharmaceutical company focused on dermatology, announced today that global sales volumes of the Levulan® Kerastick®, an integral part of the Levulan® Photodynamic Therapy (PDT) technology platform, surpassed one million units.
"The achievement of this milestone signifies that dermatologists in the U.S. and abroad continue to embrace Levulan PDT for Grade 1 and 2 actinic keratoses (AKs) of the face and scalp and the beneficial outcomes it offers their patients," said Bob Doman, DUSA's President and Chief Executive Officer.
"We believe that Levulan PDT is one of the fastest growing office based procedures in dermatology today, having achieved a 39% compounded annual growth rate in worldwide Kerastick revenues over the past four years," continued Doman.
"PDT is an important, versatile technology that should be integrated more frequently in clinical dermatology practice," said Jill Waibel, M.D., a dermatologist in private practice at Palm Beach Esthetic Dermatology & Laser Center, West Palm Beach, Florida.
"We are excited to have reached the one million Kerastick sales milestone, and believe that significant growth potential exists for Levulan PDT in the treatment of AKs and other potential indications," Doman concluded.
DUSA continues to explore other potential indications for the utilization of Levulan PDT for the treatment of various skin conditions and has initiated a pilot study on Levulan PDT for the treatment of AKs and the prevention of new non-melanoma skin cancer in chronically immunosuppressed solid organ transplant recipients.
SOURCE DUSA Pharmaceuticals, Inc.